# Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
Canonical URL: https://biopharmsignal.com/news/HROW/harrow-to-report-fourth-quarter-and-year-end-2025-financial-results-after-market-6a9b3ddf
Ticker: HROW
Company: Harrow, Inc.
Source: Harrow, Inc.
Published: 2026-02-18 12:00 EST
## Summary

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026...

## Article Body
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026

February 18, 2026 07:00 ET | Source: Harrow, Inc.

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com . Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update.

Conference Call Information Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.

About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn .

Contact: Mike Biega VP of Investor Relations & Communications mbiega@harrowinc.com 617-913-8890
## Recent Company News
- 2026-07-27 11:00 EST — [Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026](https://biopharmsignal.com/news/HROW/harrow-to-report-second-quarter-2026-financial-results-after-market-close-on-aug-38f34b84) — Source: Harrow, Inc.
- 2026-07-20 12:00 EST — [Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026](https://biopharmsignal.com/news/HROW/samsung-bioepis-and-harrow-present-interim-data-from-a-large-scale-post-marketin-f2b635bb) — Source: Harrow, Inc.
- 2026-07-20 11:00 EST — [Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting](https://biopharmsignal.com/news/HROW/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asr-8b380ee4) — Source: Harrow, Inc.
- 2026-07-01 11:00 EST — [Harrow Announces Commercial Launch of BYOOVIZ® in the United States](https://biopharmsignal.com/news/HROW/harrow-announces-commercial-launch-of-byooviz-in-the-united-states-234ff9de) — Source: Harrow, Inc.
- 2026-06-10 11:00 EST — [Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare](https://biopharmsignal.com/news/HROW/harrow-re-launches-verkazia-cyclosporine-ophthalmic-emulsion-0-1-for-vernal-kera-d7c7e3c9) — Source: Harrow, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)